Monthly Archives: March 2023

Slice Onboards 4 New Distribution Partners for Small Business Insurance

NEW YORK–(BUSINESS WIRE)–Slice Labs Inc. (Slice), a technology company with the first on-demand insurance platform and products to protect small businesses, has onboarded four additional wholesaler insurance agencies to Slice’s platform, allowing retail agents and brokers associated with these four partners to digitally quote and bind General Liability under the digital brand, AERO Insurance Services. The four wholesalers have partnered with Cornerstone Underwriting Partners (CUP) and are par

Employees at New Jersey’s Valley Wellness Medical Marijuana Dispensary Welcome Spring by Voting to Unionize With UFCW

WEST BERLIN, N.J.–(BUSINESS WIRE)–Employees at Valley Wellness – one of NJ’s first stand-alone medical dispensaries – vote to join UFCW Local 360.

Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Rite Aid Corporation (RAD) Investors of Class Action and to Actively Participate

NEW YORK–(BUSINESS WIRE)—- $RAD #classaction–Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Rite Aid Corporation (NYSE:RAD) (“Rite Aid” or the “Company”) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Rite Aid securities between April 26, 2018 and March 13, 2023, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:

Item 9 Labs Continues Dominating the Arizona Market With a 30% YOY Unit Sales Increase in February

PHOENIX–(BUSINESS WIRE)—- $INLB #cannabis–Item 9 Labs dominates AZ market with a 30% YOY unit sales increase in February and Spring 2023 Errl Cup podium finish for Dosi Whoa flower.

Virpax Pharmaceuticals Reports 2022 Year-End Results

BERWYN, Pa.–(BUSINESS WIRE)– #earnings–Virpax Reports 2022 Year-End Results

CDC Warns Deadly Drug Resistant Candida auris Spreading Rapidly Across US

MOUNT VERNON, N.Y.–(BUSINESS WIRE)–Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), a leading provider of best in class suite of proprietary, patented, scientific and clinically proven, surface and air disinfection technologies (fixed, mobile and HVAC), LED lighting products and hotel furnishings used by clients globally, announces today, the Center of Disease Control (CDC) has warned that Candida auris (C. auris) is spreading rapidly through U.S. health care facilities. As

Brown-Forman Announces $650 Million Debt Offering

LOUISVILLE, Ky.–(BUSINESS WIRE)–Brown-Forman Corporation (NYSE: BFA, BFB) today announced the pricing of a $650 million 10-year senior unsecured note. The 4.750% 10-year senior notes are due April 15, 2033. Brown-Forman intends to use the net proceeds from the offering to refinance its existing $600 million of outstanding debt under its senior unsecured 364-day term loan credit agreement, with the remainder to be used for general corporate purposes. BofA Securities, Inc., Citigroup Global Mar

Aelis Farma Has Participated in Two Symposiums Marking World Down Syndrome Day

BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, eligible for PEA-PME equity savings plans) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its participation in two symposiums marking World Down Syndrome Day. The 18th World Down Syndrome Day Colloquium (Bourg-en-Bresse, France, March 17-19, 2023) Pier Vincenzo Piazza, CEO of Aelis Farma, spoke on March 1

Ally Biotech Announces Acquisition of Popular THC “Chill Pill” Soft Gel Cap Line From Desert Medical Campus, Inc.

PAYSON, Ariz.–(BUSINESS WIRE)– #Cannabis–Ally Biotech, a science-based company and provider of leading-edge bioactive cannabinoid delivery solutions, today announced the acquisition of the popular Chill Pill™ brand, an extensive line of soft, easy-to-swallow soft gel caps and all of its assets, from Desert Medical Campus, in an all-cash transaction. The Chill Pill brand, founded in 2018 by Andrew Provencio at his Desert Medical Campus facility, offered the first THC soft gel cap on the market in Arizona

POSaBIT Expects FY 2023 Revenue of $60 to $63 Million, Gross Profit of $15 to $17 Million and to Resume Profitability on an Adjusted EBITDA Basis

TORONTO & SEATTLE–(BUSINESS WIRE)–POSaBIT Systems Corporation (CSE: PBIT, OTC: POSAF) (the “Company” or “POSaBIT”), a premier point-of-sale and payments provider for the cannabis industry, today provided financial guidance for 2023. 2023 Financial Guidance The Company provides the following guidance for the full year 2023.   Full Year 2023 Guidance1   (as of March 20, 2023, in US dollars)     Total Revenue $60 to $63 million Gross Profit $15 to $17 million Adjusted EBITDA2 Positive 1 Does not

Adnant Consulting Transforms Unrivaled Brands With 41% Reduction in Debt in Bear Cannabis Market

LOS ANGELES–(BUSINESS WIRE)–Adnant Consulting (the Company), a national cannabis accountancy, has spent almost a decade leveraging its financial and regulatory expertise, as well as its industry relationships, to take cannabis startups like Green Thumb Industries, Glass House Brands and MedMen to public markets. Now the Company is demonstrating its acumen in reviving troubled businesses through strategic executive placement, turning to its proven leadership to generate rapid fiscal turnaround

Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has established Enveric Therapeutics Pty. Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic. Enveric Therapeutics will